See article

Therapeutic benefits of S. boulardii CNCM I-745 are backed with strong clinical and scientific evidence

  • 5 min

The probiotic drug Saccharomyces boulardii CNCM I-745 has scientifically and clinically proven benefits to address diarrhea

The single-strain yeast probiotic Saccharomyces boulardii CNCM I-745 is indicated for the prevention and treatment of diarrhea in adults and children.1 These recommendations are based on both non-clinical investigations and high quality robust clinical studies.2


Saccharomyces boulardii CNCM I-745 has strong clinical evidence leading to multiple recommendations as a treatment and prevention for diarrhea

The efficacy of S. boulardii CNCM I-745 to prevent and treat diarrhea has been demonstrated in numerous clinical studies investigating diarrhea due to causes including infectious diarrhea and antibiotic treatments in both adults and children.2

These clinical findings have led to the classification of S. boulardii CNCM I-745 as a probiotic drug2,*, which means that this probiotic is backed by strong, good quality clinical evidence, as well as meeting the strict manufacturing requirements for a biological drug classification.2

The wealth of clinical evidence of the multiple proven health benefits of S. boulardii CNCM I-745 supports its use for gastrointestinal disorders including :

  • management and prevention of acute diarrhea1 ;
  • prevention of antibiotic-associated diarrhea1 ;
  • prevention of recurrent Clostridium difficile infections following antibiotic treatment1 ;
  • prevention of Helicobacter pylori eradication treatment-associated side effects.1

Furthermore, because of the strong non-clinical and clinical evidence that has been generated with S. boulardii CNCM I-745, the health benefits and use of this yeast probiotic drug in both adults and children are endorsed by multiple scientific societies, including:

  • The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)5,6 ;
  • The World Gastroenterology Organisation7 ;
  • Recommendations for probiotics in paediatric and adult gastrointestinal disease in the Asia-Pacific Region8,9 ;
  • Recommendations of the Latin-American expert consensus group for the use of probiotics in paediatric gastroenterology10 ;
  • Maastricht V/Florence Consensus Report for the management of H. pylori.11


*In the majority of countries where S. boulardii CNCM I-745 is available.


Saccharomyces boulardii CNCM I-745 multiple specific mechanisms of action to address diarrhea and restore microbiota balance

Non-clinical scientific studies have investigated and demonstrated that S. boulardii CNCM I-745 has multiple, specific mechanisms of action against the causes and symptoms of diarrhea and intestinal dysbiosis including:

  1. Anti-microbial activity
    • Produces 3 proteins that target the toxins produced by pathogenic bacteria3 ;
    • Binds pathogenic bacteria and strengthens tight junctions to prevent invasion3 ;
  2. Anti-inflammatory activity2 ;
    • Reduces the production of anti-inflammatory cytokines2 ;
  3. Immune stimulation2 ;
    • S. boulardii CNCM I-745 stimulates the production of secreted immunoglobulin A that targets pathogenic microbes.2
  4. Positive effects on gut function2 ;
    • Stimulates production of short-chain fatty acids
    • that increase fluid absorption2
    • Produces polyamines, substances involved in maintaining healthy enterocytes.2
  5. Restoration of gut microbiota composition and diversity.4
    • Through its multiple mechanisms of action, S. boulardii CNCM I-745 has been demonstrated to rapidly restore the composition and diversity of beneficial microbiota4 that contribute to normal gut functioning such as fermentation and the metabolism of nutrients.4
      • In part by preventing the overgrowth of pathogens that outcompete with the microbiota, and also creating a positive growth environment for the microbiota.4

In particular, specific mechanisms of action against potentially dangerous pathogens that cause diarrhea3 has been demonstrated, where the yeast :

  • Destroys the toxins produced by Clostridium difficile, Cholera toxin, as well as the toxic lipopolysaccharide of Escherichia coli3 ;
  • Binding to invasive pathogens such as Salmonella typhimurium and increasing its elimination from the gut3 ;
  • Produces capric acidthat inhibits Candida albicans virulence2.



Internal code : 20.44


  • 01 . S. boulardii CNCM I-745 Summary of Product Characteristics.
  • 02 . Joly F et al. Saccharomyces boulardii CNCM I-745. In: Marteau P, Dore J, eds. Gut Microbiota: A Full-Fledged Organ. Paris: John Libbey Eurotext; 2017:305-350.
  • 03 . Czerucka D, Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World journal of gastroenterology. 2019;25(18):2188-2203. doi:10.3748/wjg.v25.i18.2188
See more See less
  • 04 . Moré MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – A review. Clinical and Experimental Gastroenterology. 2015;8:237-255. doi:10.2147/CEG.S85574
  • 05 . Guarino A et al. European society for pediatric gastroenterology, hepatology, and nutrition/european society for pediatric infectious diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. Journal of Pediatric Gastroenterology and Nutrition. 2014;59(1):132-152. doi:10.1097/MPG.0000000000000375
  • 06 . Szajewska H et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. Journal of Pediatric Gastroenterology and Nutrition. 2016;62(3):495-506. doi:10.1097/MPG.0000000000001081
  • 07 . Guarner F et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. 2017:1-35.
  • 08 . Cameron D et al. Probiotics for gastrointestinal disorders: Proposed Recommendations for children of the Asia-Pacific region. World Journal of Gastroenterology. 2017;23(45):7952-7964. doi:10.3748/wjg.v23.i45.7952
  • 09 . Ghoshal UC et al. The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region – background and recommendations of a regional consensus meeting. Journal of Gastroenterology and Hepatology (Australia). 2018;33(1):57-69. doi:10.1111/jgh.13840
  • 10 . Cruchet S et al. The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American Experts. Pediatric Drugs. 2015;17(3):199-216. doi:10.1007/s40272-015-0124-6
  • 11 . Malfertheiner P et al. Management of helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30. doi:10.1136/gutjnl-2016-312288
Find the brand name
in your country
We are present in more than 90 countries
Some related
  • Why Saccharomyces boulardii CNCM I-745 is efficient?
    ExpandCollapseSee more
  • How does Saccharomyces boulardii CNCM I-745 work and how is it adapted to address diarrhea?
    ExpandCollapseSee more
  • Is Saccharomyces boulardii CNCM I-745 recommended by international gastroenterology societies?
    ExpandCollapseSee more
You are
Choose language